Industry Updates for the Psychedelics World | Page 22 of 35

Psychedelics News

Industry

19 Aug 2022

Hanging On or Closing Shop? Mydecine Announces $245K Financing

Today's announcement of a $245K in capital infusion could, perhaps, maybe, signal something hopeful for investors....

By Microdose NewsDesk

Industry

18 Aug 2022

MindMed’s Path Through the Clinical Trial Process

On January 25th, 2022 the Food and Drug Administration (FDA) cleared MindMed’s MM-120 Investigational New Drug (IND), an LSD-based drug directed at treating generalized anxiety disorder, the first of its...

By Robert Toland

Industry

17 Aug 2022

Cybin Granted Schedule I DEA License for CYB003 Phase 1/2a Trial

Cybin and Clinilabs have been granted Schedule I DEA License for CYB003 Phase 1/2a clinical trial...

By Microdose NewsDesk

Industry

16 Aug 2022

Atai Reports Q2 2022 Financial Results & Business Update

Q2 results show that Atai has up to 487M to continue developing next-generation mental health treatment....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance, Industry

15 Aug 2022

atai Life Sciences Secures $175 Million Loan

The new loand plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments...

By Microdose NewsDesk

Industry

12 Aug 2022

Field Trip & Reunion Announce $19.9 Million Private Placement Financing

First day of trading for both Reunion and Field Trip Health & Wellness expected to occur on or about August 17, 2022....

By Microdose NewsDesk

Breaking News, Industry

12 Aug 2022

Breaking News: MindMed Halts 18-MC (MM-110) Opioid Withdrawal Program

Yesterday MindMed released its financial results and held its earnings call, announcing the shelving of its 18-MC (MM-110) program for opioid withdrawal....

By Jason Najum

Industry, Science

10 Aug 2022

Democratizing Health Research: An Interview with Quantified Citizen

Quantified Citizen is an app and digital platform that allows researchers to access large numbers of participants for a variety of studies, while simultaneously giving people the opportunity to self-examine...

By Jason Najum

Industry

10 Aug 2022

Microdosing Collective: New Non-Profit Promotes Low-Dose Psychedelics

New Non-Profit Group Promotes Regulated Use of Sub-Perceptible Psychedelics as Legal Wellness Supplements...

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result